AKBA (Akebia Therapeutics Inc) Gross Profit Margin

Official company branding of Akebia Corp (AKBA)

Akebia Therapeutics (AKBA) maintains a stable staff of regulatory and go-to-market experts. The development of new agents is based on AI algorithms and automated synthesis. Company revenues rely on the supply of Vafseo to pharmacies and dialysis centers. Sales margins reflect cost dynamics, where the value 78.20 denotes the current production efficiency metric.

AKBA: Akebia Therapeutics, Inc. Gross Margin 07/04/2022 - 11/21/2026

Comprehensive metric breakdowns and analytics for Akebia Therapeutics (AKBA)

- business market valuation indicators:
Summary company analysis:Akebia Therapeutics, Inc. - AKBA
Manufactured product of Akebia Corp

For Akebia Therapeutics (AKBA), the gross profit margin reflects the efficiency of monetizing patents for anemia drugs amid price regulations imposed by government programs. This indicator is calculated as the ratio of the difference between revenue and direct cost of goods sold to total sales, allowing investors to assess the business's fundamental ability to generate profit before accounting for operating expenses.